Adenocarcinoma contains more immune tolerance regulatory T-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer

Lung

Volumn 191, Issue 3, 2013, Pages 265-270

  Black, Candice C ^a   Turk, Mary Jo ^b   Dragnev, Konstantin ^a   Rigas, James R ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NORRIS COTTON CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; FoxP3; Lung cancer; Regulatory T cells; Tregs

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADENOCARCINOMA; ARTICLE; CANCER SURGERY; CANCER THERAPY; FIBROSING ALVEOLITIS; HUMAN; IMMUNOLOGICAL TOLERANCE; LUNG NON SMALL CELL CANCER; LYMPH NODE; LYMPHOID TISSUE; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; T-LYMPHOCYTES, REGULATORY; TISSUE ARRAY ANALYSIS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84878714331     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9455-7     Document Type: Article

References (21)

1. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545
2. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155(3):1151-1164
3. Sutmuller RP, Van Duivenvoorde LM, Van Elsas A et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25 regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194(6):823-832
4. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4 CD25 regulatory T cells. Nat Immunol 4(4):330-336
5. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057-1061
6. Wolf D, Wolf AM, Rumpold H et al (2005) The expression of the regulatory T cell-specific forkhead box transcription factor Foxp3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11(23):8326-8331
7. Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169(5):2756-2761
8. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4CD25 regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98(5):1089-1099
9. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9(12):4404-4408
10. Halpern AC, Schuchter LM (1997) Prognostic models in melanoma. Semin Oncol 24(1 Suppl 4):S2-S7
11. Gajewski TF, Meng Y, Blank C et al (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213(1):131-145
12. Petersen RP, Campa MJ, Sperlazza J et al (2006) Tumor infiltrating Foxp3 regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107(12):2866-2872
13. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K (2010) Tumor-infiltrating Foxp3+ regulatory t cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 5(5):585-590
14. Lynch TJ, Bondarenko I, Luft A et al (2011) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046-2054
15. Brahmer JR, Horn L, Antonia S et al (2012) Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer. J Clin Oncol 30(2 suppl):abstr 7509
16. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumors (International Union against Cancer), 7th edn. Wiley-Blackwell, New York, pp 136-146
17. Huh JW, Lee JH, Kim HR (2012) Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg 147(4):366-372
18. Esendagli G, Bruderek K, Goldmann T et al (2008) Malignant and nonmalignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 59(1):32-40
19. Woo EY, Yeh H, Chu CS et al (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168(9):4272-4276
20. Schneider T, Kimpfler S, Warth A et al (2011) Foxp3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 6(3):432-438
21. Staples CA, Muller NL, Miller RR, Evans KG, Nelems B (1988) Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology 167(2):367-372